undamentalytics Newsletter
Sign in

Aurinia Pharmaceuticals Inc. balance sheet

At the end of fiscal 2025, Aurinia Pharmaceuticals Inc. had total assets of $752m, total liabilities of $170m and shareholders' equity of $581m. It held $80.2m in cash against $0 of debt: net cash of $80.2m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents401661183062722329449838046
Receivables———00151324374147
Inventory———014192540394644
Total current assets———315419513443425447492588
Total assets———324464543471548551752826
Accounts payable———————4533
Deferred revenue (current)—————03511410
Total current liabilities———1132414677989496
Total debt——000000000
Total liabilities———26566465170173170168
Shareholders' equity—178136299408479405378377581658
Net debt (negative = net cash)−40−166−118−306−272−232−94−49−83−80−46
Shares outstanding——86m112m127m142m142m144m141m132m134m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: AUPH vs IOVAARVN vs AUPHADPT vs AUPH

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aurinia Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aurinia Pharmaceuticals Inc.